10th IAS Conference on HIV Science | 21-24 July 2019 | Mexico City, Mexico


First Look: Scientific programme highlights

posted on

01 May 2019 (Geneva, Switzerland)

What’s really exciting about IAS 2019 is that in addition to the strong science, the programme presenters embody the diversity of our research community. IAS 2019 will celebrate new voices of young investigators and leading women in science. This programme will provide important new insights, ask probing questions and challenge the status quo.

Anton Pozniak, IAS 2019 Co-Chair and Scientific Programme Committee member

Here’s your first glimpse of the scientific programme for the 10th IAS Conference on HIV Science (IAS 2019).

Through a highly competitive abstract review process, IAS 2019 will offer an exceptional scientific programme. The research will be more diverse than ever and so will the speakers, with women representing more than half of the presenters and nearly 40% of the presenters under the age of 35.

Browse some of what you can expect to see in Mexico City this July.

Advances in HIV treatment and cure research

  • New findings from key drug trials, including a Phase III study of a novel HIV attachment inhibitor in patients with multi-drug resistant HIV
  • Latest data on the potential link between dolutegravir (DTG) and neural tube birth defects
  • Progress in cure research, including data on the safety and activity of vesatolimod, a toll-like receptor 7 agonist, in people with HIV
  • New insights from further analysis of data from RIVER, the first randomized controlled trial to assess a “kick and kill” HIV eradication strategy

New research on HIV co-infections

  • An evaluation of rapid diagnostic tests for hepatitis C in patients from low- and middle-income countries, including patients with and without HIV
  • New data on HCV reinfection among people with HIV
  • A study on survival trends for people living with HIV, with and without TB co-infection, in Latin America

Latest progress in biomedical HIV prevention

  • Final results from an open-label extension trial of the dapivirine vaginal ring
  • New data on global uptake of pre-exposure prophylaxis (PrEP)
  • Updates from the ANRS Prevenir study of daily versus on-demand PrEP
  • Progress in the development of long-acting implants for PrEP
  • Two-year post-vaccination data from the APPROACH vaccine study

Insights on vulnerable populations

  • Studies identifying prevention strategies that could curb the spread of HIV among adolescents in sub-Saharan Africag
  • New research on innovative strategies to increase PrEP adherence among youth
  • Insights on the link between criminalization of sex work and the spread of HIV

Media contact
Mandy Sugrue
Communications Director
[email protected]